Shaun A. Kirkpatrick
President, Biotechnologies
Kirkpatrick has more than 25 years experience managing venture investments and technology development programs in the fields of cancer, inflammation, metabolic disease and neurological disorders, and technology platforms related to biotherapeutics and life science tools. He oversees RCT’s venture investments, technology development programs and special licensing programs in therapeutics, life science tools and diagnostics. He is a member of the board of directors for several start-up biomedical companies and ventures. Kirkpatrick is also a founding member of the board of directors for the Critical Path Institute, an institute formed with the U.S. Food and Drug Administration to accelerate the development of safe human therapeutics.
Professional Experience
- Research Corporation Technologies
President, Biotechnologies 2013–present
President & Chief Executive Officer, 2005–2013
President & Chief Operating Officer, 2004–2005
Vice President & Managing Director, 2001–2004
Director, Commercialization, 1999–2000
Venture Development Associate, 1993–1999
Board Membership
- Research Corporation Technologies, Inc. Director, 2004-present
- AustinPx™, LLC Chairman, 2014–present
- Pheon Therapeutics Director, 2015-present
- Codis™ Director, 2021-present
- Translational Drug Development, LLC Chairman, 2020-present
- The Critical Path Institute Director, 2005–present
- Flinn Foundation Director, 2008–present
- Thomas R. Brown Foundations Trustee, 2015-present
- University of Arizona College of Pharmacy Director, 2005-present
Past Board Membership
- Alimmune LLC
- APT Pharmaceuticals Inc.
- Cylene Pharmaceuticals Inc.
- Imagine Pharmaceuticals Inc.
- Prolifia Inc.
- Sertoli Technologies, Inc.
- Therapeutic Human Polyclonals Inc.
Education
- Johns Hopkins University School of Advanced International Studies
M.A., International Economics and Science/Technology in International Relations - The University of Arizona
B.A., Biology and Economics